Skip to content

Study · Animal study (in vivo) · mouse · 2016

1 result

Disruption of Gpr45 causes reduced hypothalamic POMC expression and obesity.

Cui J, Ding Y, Chen S, Zhu X, Wu Y, Zhang M, Zhao Y, Li TR, Sun LV, Zhao S, Zhuang Y, Jia W and 4 more

Show all authors

Xue L, Han M, Xu T, Wu X

The Journal of clinical investigation8 Aug 2016Cited by 38 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Gpr45 mutant mice, intraventricular melanotan-2 suppressed adult obesity.

    In plain wordsIn mice with a disrupted Gpr45 gene, melanotan-2 given into the brain suppressed obesity in adulthood.

    Outcome
    DecreaseAdult obesity in Gpr45 mutant mice
    Study

    mousen: not reported in source

    Gpr45 mutant mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intraventricularAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with this finding, intraventricular administration of melanotan-2, an analog of the POMC derivative α-MSH, suppressed adult obesity in Gpr45 mutants.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.